uniQure (NASDAQ:QURE) Insider Walid Abi-Saab Sells 1,350 Shares

uniQure (NASDAQ:QURE) insider Walid Abi-Saab sold 1,350 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total transaction of $13,891.50. Following the sale, the insider now owns 151,903 shares of the company’s stock, valued at $1,563,081.87. This trade represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

uniQure Stock Performance

NASDAQ:QURE traded up $0.76 on Wednesday, reaching $12.09. 1,028,349 shares of the company’s stock were exchanged, compared to its average volume of 1,042,863. The stock has a fifty day simple moving average of $14.80 and a 200-day simple moving average of $9.89. The firm has a market cap of $589.30 million, a price-to-earnings ratio of -2.44 and a beta of 0.38. uniQure has a 52 week low of $3.73 and a 52 week high of $19.18. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51.

Hedge Funds Weigh In On uniQure

A number of large investors have recently made changes to their positions in QURE. Avoro Capital Advisors LLC purchased a new stake in uniQure during the 4th quarter worth about $38,410,000. Franklin Resources Inc. bought a new stake in uniQure during the third quarter valued at $7,360,000. RTW Investments LP grew its position in uniQure by 8,936.3% during the fourth quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock worth $15,958,000 after buying an additional 893,625 shares in the last quarter. Point72 Asset Management L.P. increased its stake in uniQure by 81.3% in the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock worth $31,282,000 after acquiring an additional 794,459 shares during the last quarter. Finally, Boxer Capital Management LLC purchased a new stake in uniQure in the fourth quarter valued at approximately $13,245,000. 78.83% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

QURE has been the subject of several analyst reports. Leerink Partners increased their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $24.00 target price on shares of uniQure in a research note on Tuesday, January 21st. Wells Fargo & Company lowered their target price on shares of uniQure from $35.00 to $30.00 and set an “equal weight” rating for the company in a report on Friday, February 28th. Mizuho upped their price objective on shares of uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 19th. Finally, Cantor Fitzgerald boosted their price objective on uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.